The humanized mAb is designed for treatment of G/GEJ adenocarcinoma whose tumors express high Dickkopf-1 protein (DKK1), following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and if appropriate, HER2/neu-targeted therapy. DKN-01 binds to and blocks the activity DKK1, a modulator of Wnt/Beta-catenin signaling.

DKN-01, which is currently being evaluated in clinical trials for gastroesophageal, gynecologic, hepatobiliary, and prostate cancers, has also received an "orphan drug" designation by the FDA for treatment of GE/GEJ cancer, Leap said.

ImmunoPrecise subsidiary expands B cell Select platform
IPA Europe, a subsidiary of ImmunoPrecise Antibodies, has expanded its foundational B cell Select platform for seamless integration into ImmunoPrecise's...

Elektrofi, Takeda partner to advance plasma protein therapeutics
Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.

Clinical test allows patients to be directly matched to clinical trial
Ashion Analytics has partnered with Elevation Oncology to match patients harboring an NRG1 gene fusion identified with Ashion's Gem Extra test with a...

Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been...

HiFiBio, ABL Bio to develop SARS-CoV-2 antibody
HiFiBio Therapeutics has partnered with South Korea-based ABL Bio to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19...